Verastem, Inc. Supplier Finance Program Obligation Current
Verastem, Inc. (VSTM) had Supplier Finance Program Obligation Current of $5.23 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:SupplierFinanceProgramObligationCurrent · last filed 2026-08-06
- 2026-06-30: Supplier Finance Program Obligation Current $5.23M.
- 2026-03-31: Supplier Finance Program Obligation Current $5.27M.
- 2025-12-31: Supplier Finance Program Obligation Current $5.30M.
| Period end | Supplier Finance Program Obligation Current |
|---|---|
| 2026-06-30 | $5.23M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $5.27M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $5.30M 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |